We have three programs, two of these programs are in clinical development and one is at an early stage of development, each is intended to treat rare and progressive kidney disease modulated by aberrant purine and uric acid metabolism.
We are currently developing XRx-008 for the treatment for progressive autosomal dominant polycystic kidney disease (ADPKD), a genetic disorder that’s known to cause declining kidney function leading to end stage kidney disease and cardiovascular disease.
Learn More
XRx-101 is a novel proprietary formulation that focuses on decreasing uric acid. The company believes that this approach has the potential to treat acute kidney and other health consequences associated with serious viral infections such as have been described for Coronavirus/COVID-19.
Learn More
We are co-developing XRx-225 for the treatment of Type 2 Diabetic Nephropathy (T2DN), one of the most common causes of chronic kidney failure and end-stage kidney disease in the U.S. and worldwide.
Learn More
We believe there is a substantial benefit to collaborating with partners, that is why we are always on the lookout for opportunities that will enable us to develop and commercialize products that not only meet the needs of both patients and physicians but will also help redefine the future of treatment options for patients with progressive kidney disease.
About our partnershipsReceive updates straight into your inbox